Equities

Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc

Actions
  • Price (EUR)3.80
  • Today's Change-0.12 / -3.06%
  • Shares traded0.00
  • 1 Year change-73.79%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Eagle Pharmaceuticals Inc grew revenues 84.56% from 171.55m to 316.61m while net income improved from a loss of 8.63m to a gain of 35.64m.
Gross margin69.84%
Net profit margin4.64%
Operating margin13.98%
Return on assets3.04%
Return on equity4.88%
Return on investment4.04%
More ▼

Cash flow in USDView more

In 2022, cash reserves at Eagle Pharmaceuticals Inc fell by 42.34m. However, the company earned 50.70m from its operations for a Cash Flow Margin of 16.01%. In addition the company used 86.83m on investing activities and also paid 6.21m in financing cash flows.
Cash flow per share2.49
Price/Cash flow per share1.70
Book value per share19.25
Tangible book value per share7.61
More ▼

Balance sheet in USDView more

Eagle Pharmaceuticals Inc has a Debt to Total Capital ratio of 21.78%, a higher figure than the previous year's 11.77%.
Current ratio2.16
Quick ratio1.67
Total debt/total equity0.2785
Total debt/total capital0.2178
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-4.75
EPS (TTM) vs
TTM 1 year ago
-48.44
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.